ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
In Situ Proliferating Peptide Nanoparticle Augments Multi-Target Intervention of Secondary Brain Damage Following Subarachnoid Hemorrhage.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Admission low-density lipoprotein cholesterol and early haematoma expansion after spontaneous intracerebral haemorrhage.Annals of medicine · 2026Article
- Predictive value of neutrophil-to-apolipoprotein A1 ratio for early postoperative cerebral infarction in patients with ruptured cerebral aneurysms.Lipids in health and disease · 2026Article
- Targeting Ferroptosis Pathways for Synaptic Protection in Sevoflurane-Induced Cognitive Impairment: A Nanomedicine Approach.CNS neuroscience & therapeutics · 2026Review
- Nanomedicine-Driven Therapeutic Strategies for Rheumatoid Arthritis-Associated Depression: Mechanisms and Pharmacological Progress.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Calcium sulfide nanoparticles as sustained HFrontiers in immunology · 2026Article
- Carbon Monoxide Nanomodulator Reverses Ischemia-Reperfusion Injury in Stroke: A Novel Dual-Channel Therapy Mode of Co-driving Neuroprotection and Neurogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Admission neutrophil-to-high-density lipoprotein cholesterol ratio and the risk of preoperative early rebleed in aneurysmal subarachnoid hemorrhage.European journal of medical research · 2025Article
- In Situ Proliferating Peptide Nanoparticle Augments Multi-Target Intervention of Secondary Brain Damage Following Subarachnoid Hemorrhage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Subarachnoid hemorrhage (SAH), a lethal stroke subtype, involves complex pathological cascades triggered by neuro-glial units for persistent neuroinflammation, oxidative damage and programmed neuronal cell death. Single-target and traditional multi-target therapies, derived from individual drugs, show limited efficacy in addressing these interconnected events, due to spatiotemporal heterogeneity of action in single-target components. This highlights the urgent need for not only new therapeutic targets, but advanced multi-target drugs. Herein, we identify elevated cell-free DNA (cfDNA), a key neuroinflammatory driver, as correlated with SAH severity and poor prognosis, suggesting its therapeutic potential. Furthermore, a novel "in situ proliferation" strategy is proposed and a flexible multi-target peptide nanoparticle is developed through co-assembling matrix metalloproteinase-2 responsive cationic peptide and glutathione peroxidase-mimicking peptide (GPXP). Upon reaching injury lesions, this system splits into two individual drugs: cationic peptide scavenges pathological cfDNA and inhibits microglia-mediated neuroinflammation, while GPXP protects neurons against oxidative damage and neuronal apoptosis/ferroptosis. Consequently, this strategy proves superior therapeutic effects on reducing secondary brain injury and promoting neurofunctional recovery in SAH mice. These findings not only highlight the essential role of cfDNA in SAH but offer a flexible resolution to advance multi-target combinational therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.